With the increasing use of GLP-1 drugs, obesity experts are now focusing on understanding 'food noise,' the internal compulsion to eat, which was previously not a primary area of study.

Biotech investor Alex Karnal has stated that GLP-1 drugs represent a 'trillion-dollar revolution' in public health, highlighting their immense potential impact on the healthcare industry.

Experts have identified five specific supplements that individuals should avoid when they are taking GLP-1 medications, such as those used for weight loss and diabetes.

New evidence suggests that GLP-1 medications provide health benefits to individuals even if they do not experience significant weight loss, expanding the understanding of their therapeutic effects.

The surging use of GLP-1 drugs is generating significant economic opportunities and creating "winners" in various industries, extending far beyond the pharmaceutical sector.

Research suggests that GLP-1 drugs such as Ozempic and Wegovy could potentially double the risk of divorce, a trend observed previously in bariatric surgery patients, according to expert warnings.

Bank of America has lowered its price target for McKesson (MCK), citing concerns over pricing pressure related to GLP-1 drugs. This adjustment reflects potential challenges for the healthcare company in the current market.

The CEO of Mars has been appointed to a board role at Novo Nordisk, a major supplier of GLP-1 drugs, signaling a significant corporate development for the pharmaceutical company.

Beyond their success as weight loss medications, GLP-1 drugs are now being investigated for their potential to help mitigate the opioid crisis, which claims over 100,000 lives annually from overdoses.

Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular risk by 22%, a new study finds.

Nutrition experts are cautioning that the increasing popularity of high-protein diets, often coupled with GLP-1 drugs and low-carb eating, is causing a significant fiber deficiency among Americans.

Scientists have discovered a molecule in python blood that suppresses appetite in obese mice without the typical side effects of GLP-1 drugs, potentially paving the way for new obesity treatments.

The evidence is tantalising. But that is not the same as proof

A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.

In recent years, a class of drugs primarily used for diabetes, now famous GLP-1 drugs due to their effectiveness against obesity, have been found to...

Increasingly popular GLP-1 drugs used to treat diabetes and obesity show promise in fighting multiple substance use disorders

A preliminary study suggests that GLP-1 drugs, typically used for diabetes and weight loss, could significantly reduce the need for migraine medication in individuals suffering from chronic migraines.

GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their experiences with the medicines.

The manufacturing process for GLP-1 medications, a class of drugs used for weight loss and diabetes, is being scrutinized for its significant environmental impact.

Scientists have identified a minimally invasive endoscopic procedure, described as a "metabolic reset," that may help prevent weight rebound in individuals who stop taking GLP-1 drugs. This method could offer lasting weight loss maintenance.

The increasing popularity of GLP-1 drugs is leading cannabis dispensaries to rethink their product offerings and business strategies.

Insurance coverage for popular GLP-1 obesity drugs is reportedly worsening, with many plans dropping or further restricting access to these blockbuster medications.

New evidence suggests that GLP-1 medications, while primarily known for weight loss, are providing health benefits to users even if they don't experience significant weight reduction. This indicates a broader therapeutic potential for these drugs.

Experts recommend incorporating strength training to help individuals preserve muscle mass when using GLP-1 medications for weight loss, addressing a common concern among users.

Flowers Foods (FLO) is experiencing business pressure due to the rising popularity of GLP-1 weight-loss treatments and a general softening of consumer sentiment, impacting its financial outlook.

As prescriptions for GLP-1 drugs have increased, doctors are reporting thirteen unexpected benefits beyond blood sugar control and weight management. However, despite their growing use, these medications are not without risks.

The CEO of Mars has been appointed to a board role at Novo Nordisk, a key supplier of GLP-1 drugs.

Canadian experts are weighing in on U.S. civil cases that expose how social media addiction negatively impacts youth, with an Indian news summary also highlighting the ongoing social media addiction trials.

Doctors specializing in obesity have responded to Polish singer Dorota Rabczewska (Doda), who controversially labeled individuals using GLP-1 drugs for obesity as "lazy" and "fat," claiming they choose a shortcut.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.

Evidence is piling up that GLP-1 drugs can treat addiction. We must learn from the way that obesity has been stigmatised In the years since so-called weight-loss jabs entered widespread use, there…

LifeMD has outlined a target of achieving over $250 million in annualized revenue run rate by the fourth quarter of 2026, driven by record demand for GLP-1 drugs and expanded partnerships.

New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.

GLP-1 Drugs Tied to Fewer Addictions, Overdoses in Large Study  Bloomberg.com

Indian comedian Tanmay Bhat shared his personal experience with weight loss, revealing he lost 75 kgs without GLP-1 injections but is now experimenting with them to see their effects.

Bank of America advises investors to buy stock in a coffee and peanut butter maker, citing easing concerns about a previous acquisition and the company's strong position to navigate the impact of GLP-1 drugs.

Researchers in Oklahoma have identified that the natural hormone FGF21 targets the same brain region as GLP-1 drugs and may reduce obesity by increasing metabolic rate rather than suppressing appetite.

Norwegian customs authorities reported a significant increase in the seizure of GLP-1 drugs, the active ingredient in weight loss injections, from fewer than ten in 2023 to over 6,200 last year.

GLP-1 medications like Ozempic and Mounjaro, popular for diabetes and obesity treatment, are being examined for their specific effects on the stomach and intestines.

The family behind Tapito, an iconic LA hot sauce, decided to sell their business due to a surge in demand for hot sauce and other condiments, attributed to the growing use of weight-loss drugs like GLP-1s.

New research indicates that individual genetic variations play a significant role in determining the effectiveness of GLP-1 drugs for weight loss and the likelihood of experiencing their side effects.

Equity research firm Bernstein estimates that apparel retailers could see an annual boost of up to $13 billion in spending as millions of people using GLP-1 drugs refresh their wardrobes due to weight loss.

The Indian government has issued a detailed advisory and increased regulatory surveillance on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision due to rising demand and flagged risks.

A columnist discusses her conflicted feelings as body-positivity influencers she follows begin taking GLP-1 drugs, expressing a desire for them to remain 'chubby'.

A new study indicates that the cardiovascular benefits gained from GLP-1 medications are lost more rapidly after treatment cessation than they were acquired.

Nutritionists are offering guidance on adopting 'GLP-1 friendly' diets for individuals using GLP-1 drugs for weight management, helping to decode new marketing labels from food companies targeting this demographic.

GLP-1 drugs, while offering significant therapeutic advancements, are also susceptible to misuse, raising concerns about their broader implications beyond intended medical applications.

American restaurant chains are reconsidering both menus and portion sizes after the use of so-called GLP-1 drugs, such as Ozempic, Wegovy, and Zepbound, has increased significantly.

Companies producing sauces and spices are seeing increased deal interest, as the rise of GLP-1 weight-loss drugs is reportedly leading Americans to seek out more flavorful, 'hot stuff'.

RESEARCH reveals that popular GLP-1 drugs used for weight loss can significantly increase the risk of osteoporosis and other bone diseases, as well as tendon ruptures.

A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose.

A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and that many more would like to, but cost is a barrier.

Eli Lilly's stock declined after its competitor, Novo Nordisk, announced plans to reduce the list prices for its GLP-1 class of drugs.

The initial excitement surrounding GLP-1 weight loss drugs provides insights into current market dynamics, with connections drawn to jet fuel and software sell-offs.